Shenzhen TargetRx, Inc.
- Country
- 🇨🇳China
- Ownership
- Holding, Joint Venture
- Established
- 2014-08-04
- Employees
- 1
- Market Cap
- -
TGRX-678 Phase I Oral Pharmacokinetic Study
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06697899
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
- Conditions
- Hematologic MalignancyNon Small Cell Lung CancerAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06484816
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06453902
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
TGRX-326 Pharmacokinetic Mass Balance
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06438367
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06304805
- Locations
- 🇨🇳
First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China
TGRX-326 Pharmacokinetic Drug Interaction
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Efavirenz+TGRX-326Drug: Itraconazole+TGRX-326
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT06294561
- Locations
- 🇨🇳
Nanjing Drug Tower Hospital, Nanjing, Jiangsu, China
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesHematologic MalignancyAcute Lymphoblastic Leukemia, AdultNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06206174
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06088888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 321
- Registration Number
- NCT06082635
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shenzhen TargetRx, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT05955391
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China